The monocarboxylate transporter MCT family member MCT1 can transport lactate into and out of tumor cells. While most oxidative cancer cells import lactate through MCT1 to fuel mitochondrial respiration, the role of MCT1 in glycolysis-derived lactate efflux remains less clear. In this study we identified a direct link between p53 function and MCT1 expression. Under hypoxic conditions, p53 loss promoted MCT1 expression and lactate export produced by elevated glycolytic flux, both in vitro and in vivo. p53 interacted directly with the MCT1 gene promoter and altered MCT1 mRNA stabilization. In hypoxic p53
INTRODUCTION.
Among the large family of monocarboxylate transporters (MCT), four of them are described as H + /lactate symporters capable of bidirectional transport of lactic acid across the plasma membrane (1) . MCT1 is the most ubiquitous, MCT2 and MCT3 expressions are limited to some tissues and MCT4 is usually described as the hypoxia-inducible MCT family member. MCT4 is actually the prototypical MCT responsible for the efflux of glycolysis-derived lactate occurring under hypoxia in tumors (2) (3) (4) or in some specialized cells (1, (5) (6) (7) . In the skeletal muscle, in particular, MCT4 transports lactate outside the cells of white muscle fibres. Interestingly, MCT1 expressed in red-oxidative muscle fibres will in turn facilitate the uptake of lactate which will be used after conversion into pyruvate as an alternate carbohydrate fuel source (6, 7) . Similar lactate exchange and uptake through MCT1 is reported in the heart (8) , red blood cells (9) and even in the liver to support gluconeogenesis (10) . Within tumors also, we and others recently documented that cancer cells could import lactate through MCT1 from the most glycolytic tumor cells (11) (12) (13) (14) or tumor-associated fibroblasts (15, 16) to fuel mitochondrial respiration and thereby spare glucose for hypoxic tumor cells.
In many tumor cell lines characterized by an elevated glycolytic flux even in the presence of oxygen (the Warburg effect) (17), the reported expression of MCT1 supporting lactate influx is thus somehow paradoxical (11, 18) . A simple explanation could be that MCT1 can function in the reverse mode according the environmental conditions. One could therefore envision that in tumor Author Manuscript Published OnlineFirst on December 19, 2011; DOI: 10.1158/0008-5472. CAN-11-2474 factor (19) and the already well characterized links between metabolism and P53 genetic alterations (20, 21). Physiologically, P53 regulates the cell energy balance between glycolysis and oxidative phosphorylations (OXPHOS). p53 can for instance promote mitochondrial respiration by increasing the expression of SCO2 (synthesis of cytochrome c oxidase 2 SCO2, a key regulator of cytochrome c oxidase complex) (22). P53 also restrains the glycolytic rate through the expression of TIGAR (TP53-induced glycolysis regulator) (23). Loss of P53 is therefore associated with a stimulation of glycolysis, thereby supporting the Warburg effect. This may require the need to deal with high levels of lactate, a phenomenon yet exacerbated under hypoxic conditions. In this work, we studied the influence of elevated extracellular and intracellular lactate concentrations on MCT1 expression in a variety of tumor cells and examined whether the P53 status could account for a different capacity to handle these changes in lactate homeostasis. 
RESULTS.
MCT1 mRNA expression is influenced by hypoxia but not by extracellular lactate.
We previously documented that lactate could enter some tumor cells through the MCT1 transporter to fuel oxidative metabolism (11) while in other cells, this transporter was reported to release lactate to the extracellular medium (27) . To study the rationale behind this distinct behavior, we examined the influence of either the addition of extracellular lactate or the Figure 1A ). In vitro and in vivo MCT1 protein expression is regulated by hypoxia in a p53-dependent manner.
To further explore the existence of a potential link between the cell P53 status and MCT1 expression, we then focused on WT and P53 -/-HCT116 cells. We found that after 72 hours of hypoxia, MCT1 protein was significantly decreased in P53 WT HCT116 but increased in P53
-/-HCT116 ( Figure 2A ). In parallel, we also examined MCT4 expression in both cell types and found that MCT4 expression was rapidly induced by hypoxia but rapidly returned to basal level, independently of the cell genotype origin (Suppl. Figure 1 ). Changes in MCT1 expression were confirmed by immunocytochemistry, the hypoxia-induced decrease in the expression of MCT1
(at the plasma membrane) in P53 WT HCT116 cells contrasting with the increase in expression in P53 -/-HCT116 cells ( Figure 2B ). We confirmed the parallel P53 stabilization and nuclear translocation in P53 WT HCT116 exposed to hypoxia ( Figure 2C ). We also examined whether induced protein in tumors (29) (Figure 2D ). By contrast, a perfect match between CAIX and MCT1 localization was found in P53 -/-HCT116 cells ( Figure 2D ).
Hypoxia-induced MCT1 expression allows P53
-/-HCT116 cells to release and take up lactate according to the environmental conditions.
We next aimed to determine whether changes in MCT1 expression functionally alter the manner for hypoxic tumor cells to handle lactate. We found that 72h-hypoxia stimulated lactate efflux to a larger extent in P53 -/-HCT116 cells (white bars, Figure 3A ). Interestingly, silencing MCT1 with a dedicated shRNA ( Figure 3B ) barely influenced the transport of lactate in P53 WT HCT116 but prevented lactate efflux from P53 -/-cells (black bars, Figure 3A ).
Since we previously showed that MCT1 could facilitate the uptake of lactate by oxidative tumor cells (11), we also used a protocol wherein cells were maintained under hypoxia (1% O 2 )
for 6 days and then re-oxygenated or maintained under hypoxia for 3 more days without renewing the culture medium (ie, exposing them to a naturally lactate-enriched glucose-deprived medium). This protocol led to the death of ~40% and ~50% of P53 WT HCT116 after 3 days reoxygenation or prolonged hypoxia, respectively ( Figure 3C ). By contrast, P53 -/-HCT116 did survive and significantly proliferate under both conditions ( Figure 3C ). Note that P53 -/-HCT116 proliferated to a larger extent than WT cells during the initial 6 days-hypoxic period (compare white bars in Figure 3C ). We further documented that P53 -/-HCT116 presented a higher relative glucose consumption rate (than WT cells) and importantly that extracellular lactate could subsequently be taken up during the reoxygenation phase to support P53 -/-cell growth ( Figure   3D ). To exclude that the above difference arose from the higher extracellular lactate content in P53 -/-HCT116 culture medium, we also used a protocol in which the extracellular medium was replaced after 72h-hypoxia by a glucose-free 10 mM lactate-containing medium. We found that Figure 3E ). Moreover, since MCT1 is also known to efficiently transport ketone bodies (15), we also used hydroxybutyrate-supplemented glucose-free medium and observed a similar stimulation of P53 -/-cell proliferation (vs P53 WT cells) ( Figure   3E ).
We then examined how hypoxia-induced upregulation of MCT1 in P53 -/-HCT116 cells could impact cell proliferation if lactate (instead of glucose) was available in the extracellular medium from the beginning of the experiment. We first confirmed that in these conditions, MCT1
expression was upregulated in response to hypoxia (not shown). We found that with increasing time under hypoxia, P53 -/-HCT116 grew more efficiently in the presence of lactate to reach at 72 hours a proliferation rate similar to that reached in the presence of glucose (see ratio ~1 in Figure   3F ). By contrast, in P53 WT HCT116 cells, the capacity to use lactate as energy fuel for proliferation rapidly decreased with time under hypoxia to reach ~40 % of the rate observed with glucose ( Figure 3F ). To determine whether this difference was dependent on the expression of MCT1, we silenced MCT1 as described above (see Figure 3B ). We found that in P53 -/-HCT116, MCT1 silencing prevented lactate-exposed cells to acquire the capacity to increase their proliferation rate under hypoxia (vs P53 WT HCT116) ( Figure 3G ). We also confirmed that p53 -/-HCT116 cells could take up 5-fold more lactate in these conditions than wild-type cells ( Figure   3H ). We also found that, under deeper hypoxia conditions (ie, 0.1% O2), lactate failed to be taken up by P53 -/-HCT116 tumor cells ( Figure 3H ), which in turn rapidly died in lactate-containing medium (not shown).
Lactate uptake under hypoxia is used as an alternate fuel for mitochondrial respiration.
To determine whether mitochondria were involved in the consumption of lactate under moderate hypoxia, we used 1μM rotenone to block cell respiration and found that in this condition, lactate failed to support cell survival ( Figure 3I ). Co-treatment with glucose to fuel glycolysis however completely rescued rotenone-exposed P53 -/-cells ( Figure 3I ). It is noteworthy that in P53 WT HCT116 cells, glucose only partly rescued proliferation in the presence of 1μM rotenone, confirming a higher dependency on (respiratory) oxidative metabolism (vs p53-/-HCT116 cells). Since lactate conversion into pyruvate is required to fuel mitochondrial respiration, we also examined the extent of the LDHB expression in both cell genotypes. We found that in P53 -/-HCT116 cells, LDHB expression remained significantly higher with time under hypoxia than in P53WT cells ( Figure 3J ). Interestingly, the expression of LDHA, the gene product known to promote the reverse conversion of pyruvate into lactate, was transiently increased in response to hypoxia in both cell genotypes but more rapidly returned to basal level in P53 -/-HCT116 cells (than in P53WT cells) ( Figure 3K ). We also observed a significantly higher expression of COX4-2 (the cytochrome c oxydase isoform known to support mitochondrial respiration under low pO 2 (30)) in P53 -/-HCT116 cells ( Figure 3L ).
The expression and stability of MCT1 mRNA under hypoxia are dependent on the expression of NF-κB and P53.
To understand the p53-dependent changes in MCT1 expression in HCT116 cells exposed to hypoxia, we examined possible regulation by major transcription factors known to be induced Figure 5A ). Importantly, we found that while in normoxia, there was no difference in MCT1 mRNA expression between parental and E6-silenced cells, a significant inhibition of MCT1 upregulation was observed in E6-silenced SiHa cells ( Figure 5B ).
In parallel, we also silenced P53 in the MDA-MB231 cell model of gain-of-function P53 mutation. We selected stably transfected cells with p53-targeting shRNA for their incapacity to respond to a 2 Gy irradiation with an upregulation of P53. We confirmed that P53 silencing prevented any increase in P53 expression in response to hypoxia ( Figure 5C ). Furthermore, we found that P53 knocking-down strongly induced MCT1 expression in MDA-MB231 cells (vs MCT1 downregulation observed in control MDA-MB-231 cells) ( Figure 5D ).
Breast cancer patients harboring p53 mutations in hypoxic tumors express high levels of

MCT1 together with a negative outcome.
We then aimed to search for a correlation between P53 status and MCT1 mRNA expression in a bank of needle core biopsies collected from breast cancer patients harboring wildtype P53 (n=26) or a P53 loss-of-function mutation (n=24) (33) . To integrate the hypoxia parameter in this analysis, we also examined the mRNA expression of carbonic anhydrase IX reported to be induced under low pO 2 levels. We used the median expression of carbonic anhydrase IX as a cut-off to discriminate between "hypoxic" and "normoxic" tumors. In wildtype P53 tumors, the expression level of MCT1 mRNA was not influenced by hypoxia whereas in mutated P53 tumors, MCT1 expression was significantly increased in the hypoxia group ( Figure 5E ). Moreover, when we examined overall survival among breast cancer patients with high expression of MCT1 and p53 mutated status, we found a more negative outcome than in patients harboring lower MCT1 expression ( Figure 5F ). 
DISCUSSION.
The p53 tumor-suppressor protein prevents cancer development through various mechanisms, including the induction of apoptosis and cell-cycle arrest for the maintenance of genome stability.
Recently, links between p53 and tumor metabolism were also elicited (21). In particular, p53 was documented to regulate the metabolic balance between glycolysis and OXPHOS via p53-inducible genes named TIGAR (23) and SCO2 (22). While expression of TIGAR inhibits glycolysis, expression of SCO2 increases mitochondrial oxygen consumption. As a consequence, loss of p53 stimulates glycolysis and impairs the mitochondrial respiratory chain, thereby promoting a switch in ATP production from OXPHOS to glycolysis.
Here, we show that p53 deficiency also promotes the expression of monocarboxylate transporter MCT1 under hypoxic conditions and thereby facilitates the release of lactate resulting from elevated glycolytic flux. When p53 is active, the mirror picture is observed with the repression of MCT1 expression and a lesser facilitation of the shift from oxidative metabolism to the glycolytic pathway. This observation is in line with previous reports documenting that hypoxia-induced P53 has primarily transrepression activity (19, 31, 32) . Mechanistically, we showed that the lack of P53 was associated with the stabilization of the MCT1 mRNA transcript in response to hypoxia, suggesting that, when present, P53 could act as a repressor of MCT1 expression. A similar mode of regulation was recently reported for survivin, the mRNA stability of which being increased in the absence of p53 (34) . Moreower, our ChIP experiments confirmed the direct interaction of both P53 and the co-repressor mSin3A with the MCT1 gene. In addition, we found that in P53-deficient cells, NF-κB expression was critical to support the hypoxia-induced increased in MCT1 abundance. This mode of regulation is enlightened by genetic manipulation of P53 in two distinct tumor models. Indeed, in knock-in experiments leading to P53 re-expression in SiHa cells (through silencing of HPV-driven repression of P53), we documented a reduced capacity to stimulate MCT1 expression under hypoxia. Yet more strikingly, in knock-down experiments reducing p53 expression in constitutively active P53 mutation-harboring MDA-MB231cells, we could document a dramatic upregulation of MCT1 under hypoxia. Importantly, our data also unravel an unsuspected advantage for P53 -/-cells since the upregulation of MCT1 expression not only offers the possibility to handle the excess intracellular glycolytic lactate but allows cells to survive when glucose is lacking. We indeed found that the increased expression of MCT1 under hypoxic conditions also contributes to the reverse lactate transport into the cells. We recapitulated this condition (a) by maintaining cells under hypoxic conditions then re-oxygenating them without renewing the medium (Fig 3C) , (b) by exposing cells to hypoxic conditions and then switching the medium from a glucose-to lactate-(or hydroxybutyrate-) containing solution (Fig 3E) , and (c) by exposing cells under hypoxic conditions in the presence of lactate (Fig 3F) . In each of these conditions, the upregulation of MCT1 was associated with a net survival and/or proliferation advantage due to lactate uptake. We actually showed that when glucose is lacking, lactate can fuel mitochondrial respiration under moderate hypoxia and thereby ensure cell survival and even proliferation. Three lines of evidence support this finding: (i) when glucose was made unavailable, the mitochondrial respiratory chain inhibitor rotenone or the reduction in pO 2 levels to 0.1% prevented the lactate rescue effects (ii) the LDHB/LDHA ratio is more compatible with the conversion of lactate to pyruvate (38, 39) in hypoxic P53
-/-cells (than WT p53 cells), (iii) an increase in cytochrome c oxidase isoform COX4-2 was observed, an adaptation known to optimize the capacity of the respiratory chain to work under hypoxia (30) .
In conclusion, our study identified hypoxia-induced MCT1 upregulation as an additional adaptation of P53-deficient tumor cells to the (Warburg-type) glycolytic metabolism, i.e. an increased capacity to meet the bioenergetic and biosynthetic demands of proliferating cells (40) .
Our data also unraveled the capacity of tumor cells under a moderate hypoxic environment to take advantage of the overexpression of MCT1 to work in the reverse mode, i.e. to take up lactate in order to fuel mitochondrial respiration after reconversion into pyruvate. 
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